https://www.profitablecpmrate.com/nsirjwzb79?key=c706907e420c1171a8852e02ab2e6ea4
Skip to content 
Sonnet BioTherapeutics is no longer just a cancer drug developer. Its $888 million merger will place it among the largest HYPE holders, blurring the lines between traditional finance and decentralized protocols in a high-stakes treasury experiment. According to a July 14 press release, Nasdaq-listed biotech firm Sonnet BioTherapeutics has agreed to an $888 million business … Read more
Two graduate students research chemical products in a laboratory in Xiwangzhuang Town, Zaozhuang City, Shandong province of China, on Dec. 26, 2023. Nurphoto | Nurphoto | Getty Images BEIJING — For all the attention on U.S.-China competition in artificial intelligence, new studies point to China’s rapid rise in biotechnology, especially for drug and agricultural development. … Read more
Alright, folks, buckle up because we’re diving into the wild world of biotech stocks, and today, one name is lighting up the market like a Fourth of July fireworks show: Alzamend Neuro, Inc. (NASDAQ: ALZN). As of this writing, ALZN is screaming higher in pre-market trading, up a jaw-dropping 139%—and for good reason! The company … Read more
Holy cow, folks, the market’s on fire today, and Protagenic Therapeutics (Nasdaq: PTIX) is leading the charge with one of the biggest gains we’re seeing as of this writing! This little biotech is making waves after announcing a blockbuster merger with Phytanix Bio, creating a new company that’s got Wall Street buzzing like a beehive. … Read more
As of this writing, Kiniksa Pharmaceuticals International Plc (KNSA) has seen a significant price movement in recent days, with its stock price increasing by 16.93% over the past few hours. This surge is largely due to the company’s impressive Q1 earnings report, which beat analyst estimates. Kiniksa Pharmaceuticals is a commercial-stage biopharmaceutical company that focuses … Read more
Today, almost all available birth control options are female contraceptives. Biotech company Contraline, however, claims that clinical trials for its non-hormonal and reversible male contraceptive have reached a critical milestone. In a news release published today, Contraline announced that its male contraceptive, named ADAM, proved to be effective and safe 24 months into its first … Read more
In a move that has sent shockwaves through the biotechnology sector, the U.S. Food and Drug Administration (FDA) announced yesterday its plan to replace animal testing with “more effective, human-relevant methods,” including artificial intelligence (AI) models in drug development. And one stock is leading the charge: Recursion Pharmaceuticals Inc. (NASDAQ: RXRX). Shares of Recursion Pharmaceuticals … Read more
In a move that’s got investors buzzing, Keros Therapeutics (NASDAQ: KROS) has announced a review of strategic alternatives to maximize stockholder value. This news comes as of this writing, the company’s shares have surged 14.42% today, making it one of the biggest gainers in the market. As we take a closer look at this biotech … Read more
In today’s fast-paced market, it’s not uncommon for stocks to experience sudden surges in value. But when PacBio (NASDAQ:PACB) saw its stock price jump by 12.20% today, investors took notice. As we dive into this biotechnology company’s recent performance and prospects, one thing is clear: PacBio has a lot going on. The preliminary first-quarter revenue … Read more
and RYSE Hey 360 – here are some of our top movers today! 🧨 Special Invite Only Event, TODAY (NOW) starting at 9am. Watch to see if JW can call out another 50% SPY options runner and learn how he’s finding these gems. Please register here for access to the trading room! FOCUS LIST🔎 SCNI – Up … Read more
https://www.profitablecpmrate.com/nsirjwzb79?key=c706907e420c1171a8852e02ab2e6ea4